- Lilly will invest up to $40 million in a five-year agreement with Indiana University.
- The partnership focuses on Alzheimer's, diabetes, cancer, and cell and gene therapy.
- IU LAB will lead the initiative, enhancing clinical trial infrastructure and talent development.
Partnership Overview
Eli Lilly and Company and Indiana University have entered a five-year agreement, with Lilly investing up to $40 million. The collaboration aims to expand access to clinical trials in Indiana, focusing on Alzheimer's disease, diabetes, cancer, and cell and gene therapy.
Goals and Objectives
The partnership seeks to create a best-in-class clinical trial innovation ecosystem in Indiana. It will leverage IU's research and clinical expertise alongside Lilly's biopharmaceutical innovation to advance discovery and care in key medical areas. The initiative also aims to strengthen Indiana's life sciences sector by developing future scientific and clinical talent.
Implementation Strategy
The IU Launch Accelerator for Biosciences (IU LAB) will lead the initiative, focusing on developing an AI-enabled clinical trial infrastructure. The project will enhance clinical trial design, improve patient recruitment, and boost operational efficiency. IU will initially leverage its extensive provider and patient network, expanding its reach by partnering with additional health systems across the state.
Impact and Future Plans
The collaboration is expected to accelerate the translation of discovery into new therapies and strengthen Indiana's role as a leader in high-quality, patient-centered clinical research. The agreement builds on existing IU–Lilly collaborations and provides a structure for future projects that support both organizations' research priorities and the needs of Indiana's life sciences industry.
